Reading CELU? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CELU free→Reading CELU? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CELU free→NASDAQHealth CareBiotechnologySnapshot 2026-06-15
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak, and management's recent track record has been unsteady, with frequent disruptive corporate changes. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is high, and the sector backdrop is a headwind, which may impact performance compared to sector peers, where it is typical. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $0.77. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted 0.14x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
27 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$248.
How much price usually moves either way.
On a bad day, this stock has moved -$967.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $8,341.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If they respond well to the delisting notice, it could help investor confidence. Not responding may cause more declines.
Confirms:Celularity has a plan to meet Nasdaq's listing rules on time.
Disproves:No plan is announced, or the company fails to meet compliance deadlines.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CELU yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On June 9, 2026, Celularity Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Staff (the “Staff”) of the Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days prior to the date of the Notice, the Company’s minimum Market Value of Listed Securities was below the minimum of $35 million required for conti…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CELU Celularity Inc | Typical Show detailsSector percentile: 58 of 100 | — | high |
ABBV AbbVie | Above typical Show detailsSector percentile: 85 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 78 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 100 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-15.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Celularity is focusing on strategic realignment by divesting its biomaterials business to NexGel.
Newly stated in 2026-Q2. The strategic realignment involves divesting the biomaterials business to NexGel. Revenue has declined from $18.1M in 2024-Q4 to $4.1M in 2025-Q4, indicating limited progress in offsetting the divestiture impact.
“The company implemented organizational changes in connection with its strategic realignment and divestiture of its biomaterials business.”
Celularity entered into several material definitive agreements, including with NexGel and Helena Global.
Stated in 2 of last 2 quarters. Celularity has been active in M&A, entering agreements with NexGel and Helena Global. Despite these activities, revenue decreased from $18.1M in 2024-Q4 to $4.1M in 2025-Q4, showing limited progress in revenue growth.
“Celularity entered into an Asset Purchase and Exclusive License Agreement with NexGel.”
Celularity received a notice from Nasdaq regarding non-compliance with the minimum market value requirement.
Newly stated in 2026-Q2. Celularity received a Nasdaq notice for non-compliance with market value requirements. The company's financials show a net income decline from -$13.3M in 2024-Q4 to -$24.4M in 2025-Q4, indicating challenges in improving financial health.
“Celularity received a notice from Nasdaq for failing to meet the minimum Market Value of Listed Securities requirement.”
Why it matters: The new CEO's plans could change the company's path. Good changes may help performance, but bad ones could hurt growth.
Confirms one read:Celularity has better operations since the new CEO started. They also have new plans.
Confirms the other:If performance stays poor or plans are unclear after the change, it could be a problem.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 29, 2026, Celularity Inc. (“Celularity”) appointed Rick Gonzalez as Chief Commercial Officer of Celularity. Mr. Gonzalez will report directly to Robert J. Hariri, M.D., Ph.D., Celularity’s Chairman and Chief Executive Officer. Celularity has not entered into a definitive employment agreement with Mr. Gonzalez in connection with his appointme…
Entry into a Material Definitive Agreement. As previously disclosed by Celularity Inc. (the “Company”) in its Current Report on Form 8-K filed on April 21, 2026, Helena Global Investment Opportunities 1 Ltd. (“Helena”) delivered an exchange notice pursuant to which Helena elected to exchange shares of the Company’s Series A Convertible Preferred Stock for a Convertible Promissory Note, and subsequently delivered a notice of event of default under such note. On May 21, 2026, the Company entere…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant To the extent required by Item 2.03, the information contained in
Entry into a Material Definitive Agreement. On April 17, 2026, Celularity Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Asset Purchase and Exclusive License Agreement, dated as of March 6, 2026 (the “Original Agreement” and, as amended, the “Agreement”), with NexGel, Inc. (“NexGel”). Among other things, the Amendment provides that: (i) the aggregate consideration payable to the Company under the Agreement is $13.3 million, consisting of an upfront cash pa…
“Helena Global elected to exchange shares of the Company’s Series A Convertible Preferred Stock.”